Early Intervention in Patients with Alzheimer's Disease
neuroscienceCME Multimedia SnackPremiere Date: Friday, January 15, 2016
This activity offers CE credit for:%>
- Physicians (CME)
- Pharmacists (ACPE)
All other clinicians will receive a Certificate of Attendance stating this activity was certified for AMA PRA Category 1 Credit™
Credit Expiration Date:
Sunday, January 15, 2017
Note: Credit Is No Longer Available
|Charles B. Nemeroff, MD, PhD
Professor and Chair
Department of Psychiatry
Mulva Clinic for the Neurosciences
Director, Institute of Early Life Adversity Research
Dell Medical School
The University of Texas at Austin
|Anand Kumar, MD
Lizzie Gilman Professor and Head
Department of Psychiatry
University of Illinois at Chicago College of Medicine
Alzheimer’s disease (AD) continues to be a growing health crisis. Progress has been made in our understanding of AD pathogenesis; however, there remains no currently effective treatment to delay the onset of or prevent the disease.
The pathophysiological process of AD begins many years before clinically obvious symptoms appear. In addition, the concept of a pre-symptomatic or preclinical stage of AD is gaining acceptance in the medical community. Discussion of risk factors and careful assessments of individuals 60 or older can improve recognition and help direct treatment approaches.
In this neuroscienceCME Snack, expert faculty will discuss cutting edge data that can be incorporated to meet the demands of managing complex patients in everyday clinical practice.
At the end of this CE activity, participants should be able to:
- Implement routine cognitive screening to facilitate early identification and early intervention of Alzheimer’s disease.
- Discuss the role and clinical utility of biomarkers and imaging for current use in the diagnosis and early intervention in AD.
- Discuss with colleagues the emerging science and therapies that will build tomorrow’s treatments for AD.
Supported by an educational grant from Lilly. For further information concerning Lilly grant funding visit www.lillygrantoffice.com.
Physicians, pharmacists, and other health care professionals with an interest in Alzheimer’s Disease.
CME Credit (Physicians):
CME Outfitters, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
CME Outfitters, LLC, designates this enduring material for a maximum of .5 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
CPE Credit (Pharmacists):
CME Outfitters, LLC, is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. .5 contact hours (0.1 CEUs)
Universal Activity Number: 0376-0000-15-004-L01-P (live programs)
0376-0000-16-015-H01-P (recorded programs)
Activity Type: knowledge-based
Successful completion of this CE activity includes participating in the live or recorded activity, reviewing the course materials, and following the appropriate set of instructions below within 30 days of completion of the activity:
To complete your activity evaluation and post-test online, and print your certificate or statement of credit immediately (75% pass rate required), please visit
www.CMEOutfitters.com/20082(requires free account activation).
There is no fee for participation in this activity. The estimated time for completion is 90 minutes.
Questions? Please call 877.CME.PROS
It is the policy of CME Outfitters, LLC, to ensure independence, balance, objectivity, and scientific rigor and integrity in all of their CE activities. Faculty must disclose to the participants any relationships with commercial companies whose products or devices may be mentioned in faculty presentations, or with the commercial supporter of this CE activity. CME Outfitters, LLC, has evaluated, identified, and attempted to resolve any potential conflicts of interest through a rigorous content validation procedure, use of evidence-based data/research, and a multidisciplinary peer review process. The following information is for participant information only. It is not assumed that these relationships will have a negative impact on the presentations.
Dr. Nemeroff has disclosed that he receives grants/research support from the National Institutes of Health (NIH). He serves as a consultant to Bracket (Clintara); Gerson Lehrman Group, Inc. (GLG) Healthcare & Biomedical Council; Lundbeck; Mitsubishi Tanabe Pharma Development America; Prismic Pharmaceuticals, Inc.; Taisho Pharmaceutical Inc.; Takeda Pharmaceuticals North America, Inc.; Total Pain Solutions (TPS); and Xhale, Inc. He serves on the scientific advisory boards of the American Foundation for Suicide Prevention (AFSP); Anxiety Disorders Association of America (ADAA); Bracket (Clintara);Brain & Behavior Research Foundation (BBRF) (formerly National Alliance for Research on Schizophrenia and Depression [NARSAD]); Clintara; RiverMend Health, LLC; Skyland Trail; and Xhale, Inc. He serves on the board of directors of the American Foundation for Suicide Prevention (AFSP); Anxiety Disorders Association of America (ADAA); and GratitudeAmerica, Inc. He is a stockholder of AbbVie Inc,; Bracket (Clintara); Celgene Corporation; COPKO Health, Inc.; Seattle Genetics, Inc.; Titan Pharmaceuticals, Inc.; and Xhale, Inc. His other financial income sources or equity of $10,000 or more include American Psychiatric Publishing; Bracket (Clintara); CME Outfitters, LLC; Takeda Pharmaceuticals North America, Inc.; Xhale, Inc. Dr. Nemeroff has patients for method and devices for transdermal delivery of lithium (US 6,375,990B1); method of assessing antidepressant drug therapy via transport inhibition of monoamine neurotransmitters by ex vivo assay (US 7,148,027B2).
Dr. Kumar serves as the Associate Editor of The American Journal of Geriatric Psychiatry.
Tony Graham, MD (peer reviewer) has no disclosures to report.
Robert Kennedy (planning committee) has no disclosures to report.
Sharon Tordoff, CCMEP (planning committee) has no disclosures to report.
Disclosures were obtained from the CME Outfitters, LLC staff: No disclosures to report.
Unlabeled Use Disclosure
Faculty of this CE activity may include discussions of products or devices that are not currently labeled for use by the FDA. The faculty have been informed of their responsibility to disclose to the audience if they will be discussing off-label or investigational uses (any uses not approved by the FDA) of products or devices.
CME Outfitters, LLC, the faculty, and Lilly do not endorse the use of any product outside of the FDA labeled indications. Medical professionals should not utilize the procedures, products, or diagnosis techniques discussed during this activity without evaluation of their patient for contraindications or dangers of use.
Questions about this activity? Call us at 877.CME.PROS (877.263.7767).